A5008546849- Cardiac Structural Anomalies and Repair
- Cardiac Valve Diseases and Treatments
- Aortic Disease and Treatment Approaches
- Venous Thromboembolism Diagnosis and Management
- Acute Myocardial Infarction Research
- Pericarditis and Cardiac Tamponade
- Peptidase Inhibition and Analysis
- Infective Endocarditis Diagnosis and Management
- Cell Adhesion Molecules Research
- Cardiac Arrest and Resuscitation
- Immunodeficiency and Autoimmune Disorders
- Congenital Heart Disease Studies
- Mechanical Circulatory Support Devices
- Atrial Fibrillation Management and Outcomes
- Viral Infections and Immunology Research
- Stroke Rehabilitation and Recovery
Indiana University – Purdue University Indianapolis
2021-2024
Indiana University School of Medicine
2021-2024
Indiana University Health
2023
Patients with severe aortic stenosis (AS) and left ventricular (LV) dysfunction demonstrate improvement in injection fraction (LVEF) after valve replacement (AVR). The timing magnitude of recovery patients very low LVEF (≤ 25%) surgical or transcatheter AVR is not well studied.
The timing and nature of risk factors for reoperation after the arterial switch operation in setting d-transposition great arteries requires further elucidation.A total 403 patients who underwent from 1986 to 2017 were reviewed. Institutional preference was pulmonary artery reconstruction using a pantaloon patch fresh autologous pericardium. targets coronary reimplantation identified by intermittent root distension. Multivariable analysis used identify reoperation.Median follow-up 8.6 years...
COVID-19 infection and the vaccines have been associated with rare cases of pericarditis. We present a case constrictive pericarditis (CP) following vaccine.A 19-year-old healthy male started having progressive abdominal pain, emesis, dyspnoea, pleuritic chest pain 2 weeks after second dose Pfizer vaccine. Computed tomography angiography revealed bilateral pleural effusions pericardial thickening effusion. Cardiac catheterization showed ventricular interdependence. magnetic resonance (CMR)...
Abstract: Unfractionated heparin is the most common anticoagulant used during percutaneous coronary intervention. Practice guidelines recommend an initial weight-based bolus dose between 70 and 100 U/kg to achieve target activated clotting time (ACT) of 250–300 seconds. The impact severe obesity on dosing not well studied. We performed a retrospective analysis 424 patients undergoing intervention who received for anticoagulation. collected detailed data cumulative administration measured ACT...